Laboratory studies show that Merck & Co's experimental oral COVID-19 antiviral drug, molnupiravir, is likely to be effective against known variants of the coronavirus, including the dominant, highly transmissible Delta, the company said on Wednesday. Read More
from Financial Post https://ift.tt/2Y2rooV
from Financial Post https://ift.tt/2Y2rooV
Comments
Post a Comment